First human trial launches for experimental drug BY002

NCT ID NCT07640438

Recruiting now Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is the first time BY002 is being tested in humans. It aims to check the drug's safety and how the body processes it. Healthy adults will receive either BY002 or a placebo by injection. Researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BY002
What this could lead to: If safe, this could pave the way for future studies testing BY002 as a treatment for certain conditions.
What could go wrong: This is an early Phase 1 trial in healthy people, so it cannot show whether BY002 works for any disease. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS STUDY

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 31003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.